Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
(WorldNews Germany)

ASX/Media Release IMMUTEP GRANTED UNITED STATES PATENT FOR EFTILAGIMOD ALPHA IN CHEMO-IMMUNOTHERAPY COMBINATION SYDNEY, AUSTRALIA - 11 August 2020 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number10,736,940) entitled "Combined Preparations for the Treatment of Cancer" by the United States Patent Office. This United States patent follows the grant of the corresponding European, Australian and Japanese patents (announced 23 May 2019, 21 June 2019 and...